Burning Rock Biotech (BNR) Gross Margin (2019 - 2026)

Burning Rock Biotech (BNR) has reported Gross Margin for 8 consecutive years, with 72.27% the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Margin fell 91.0% year-over-year to 72.27%; the TTM figure through Mar 2026 stood at 74.56% (up 306.0% YoY), while the FY2025 annual figure was 74.67%, up 442.0% from the prior year.
• Gross Margin came in at 72.27% for Q1 2026 at Burning Rock Biotech, down from 78.03% in the prior quarter.
• The five-year high for Gross Margin was 78.03% in Q4 2025, with the low at 63.13% in Q2 2022.
• Average Gross Margin over 5 years is 70.08%, with a median of 70.42% recorded in 2024.
• Across the five-year window, Gross Margin sank 777 bps in 2022 and surged 707 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 71.2% in 2022, then retreated by 9 bps to 64.51% in 2023, then advanced by 10 bps to 70.96% in 2024, then advanced by 10 bps to 78.03% in 2025, then slipped by 7 bps to 72.27% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 72.27%, 78.03%, and 75.1% for Q1 2026, Q4 2025, and Q3 2025 respectively.